N
Nina F. Gnädig
Researcher at Columbia University
Publications - 35
Citations - 2683
Nina F. Gnädig is an academic researcher from Columbia University. The author has contributed to research in topics: Plasmodium falciparum & Drug resistance. The author has an hindex of 19, co-authored 35 publications receiving 2053 citations. Previous affiliations of Nina F. Gnädig include Columbia University Medical Center & Pasteur Institute.
Papers
More filters
Journal ArticleDOI
K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates
Judith Straimer,Nina F. Gnädig,Benoit Witkowski,Chanaki Amaratunga,Valentine Duru,Arba Pramundita Ramadani,Arba Pramundita Ramadani,Mélanie Dacheux,Nimol Khim,Lei Zhang,Stephen Lam,Philip D. Gregory,Fyodor D. Urnov,Odile Mercereau-Puijalon,Françoise Benoit-Vical,Françoise Benoit-Vical,Rick M. Fairhurst,Didier Menard,David A. Fidock +18 more
TL;DR: The data provide a conclusive rationale for worldwide K13-propeller sequencing to identify and eliminate artemisinin-resistant parasites and imperils efforts to reduce the global malaria burden.
Journal ArticleDOI
Targeting the cell stress response of plasmodium falciparum to overcome artemisinin resistance
Con Dogovski,Stanley C. Xie,Gaetan Burgio,Jess Bridgford,Sachel Mok,James M. McCaw,Kesinee Chotivanich,Shannon Kenny,Nina F. Gnädig,Judith Straimer,Zbynek Bozdech,David A. Fidock,Julie A. Simpson,Arjen M. Dondorp,Simon J. Foote,Nectarios Klonis,Leann Tilley +16 more
TL;DR: In this article, a detailed kinetic analysis of the drug responses of K13 wild-type and mutant isolates of Plasmodium falciparum sourced from a region in Cambodia (Pailin).
Journal ArticleDOI
Artemisinin Action and Resistance in Plasmodium falciparum.
TL;DR: This work describes recent progress made in defining the molecular basis of artemisinin resistance, which has identified a primary role for the P. falciparum K13 protein and suggests potential ways to overcome resistance.
Journal ArticleDOI
Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies
M. Isabel Veiga,M. Isabel Veiga,Satish K. Dhingra,Philipp P. Henrich,Judith Straimer,Nina F. Gnädig,Anne-Catrin Uhlemann,Rowena E. Martin,Adele M. Lehane,Adele M. Lehane,David A. Fidock +10 more
TL;DR: Zinc-finger nucleases are used to genetically modify the multidrug resistance-1 transporter PfMDR1 at amino acids 86 and 184, and it is demonstrated that the widely prevalent N86Y mutation augments resistance to the ACT partner drug amodiaquine and the former first-line agent chloroquine.
Journal ArticleDOI
Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics
Annie N. Cowell,Eva S. Istvan,Amanda K. Lukens,Amanda K. Lukens,Maria G. Gomez-Lorenzo,Manu Vanaerschot,Tomoyo Sakata-Kato,Erika L. Flannery,Pamela Magistrado,Edward Owen,Matthew Abraham,Gregory LaMonte,Heather J. Painter,Roy Williams,Virginia Franco,María Linares,Ignacio Arriaga,Selina Bopp,Victoria C. Corey,Nina F. Gnädig,Olivia Coburn-Flynn,Christin Reimer,Purva Gupta,James M. Murithi,Pedro A. Moura,Olivia Fuchs,Erika Sasaki,Sang W. Kim,Christine H. Teng,Lawrence T. Wang,Aslı Akidil,Sophie H. Adjalley,Paul Willis,Dionicio Siegel,Olga Tanaseichuk,Yang Zhong,Yingyao Zhou,Manuel Llinás,Sabine Ottilie,Francisco-Javier Gamo,Marcus C. S. Lee,Marcus C. S. Lee,Daniel E. Goldberg,David A. Fidock,Dyann F. Wirth,Dyann F. Wirth,Elizabeth A. Winzeler,Elizabeth A. Winzeler +47 more
TL;DR: Genome sequencing elucidates potential drug resistance in the malaria parasite and identifies antimalarial targets and drug-resistance genes, as well as discovering hitherto unrecognized drug target–inhibitor pairs.